AASLD guidelines for treatment of chronic hepatitis B
- PMID: 26566064
- PMCID: PMC5987259
- DOI: 10.1002/hep.28156
AASLD guidelines for treatment of chronic hepatitis B
Conflict of interest statement
Potential conflict of interest: Dr. Jonas consults and received grants from Gilead. She received grants from Bristol-Myers Squibb and Roche. Dr. Chang advises Genentech, Alnylam, and Arbutus. Dr. Terrault consults for Bristol-Myers Squibb and received grants from Gilead. Dr. Bzowej received grants from Gilead, Synageva, and Ocera.
Comment in
-
AASLD practice guidelines: The past, the present, and the future.Hepatology. 2016 Jan;63(1):31-4. doi: 10.1002/hep.28345. Epub 2015 Dec 8. Hepatology. 2016. PMID: 26565582 No abstract available.
References
-
- Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662. - PubMed
-
- WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva Switzerland: World Health Organization; May 12, 2015. - PubMed
-
- Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219. - PubMed
-
- Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med. 2011;154:319–28. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical